Payment overview · 2025
General Payments
$75.43
5 reported records · 4 companies
Healthcare provider profile · identity verified
Marion E Hord, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · STUTTGART, AR · NPI 1235194481
Verified facts
What the public records show
CMS Open Payments records show Marion E Hord, M.D. received $75.43 in general payments during 2025 across 5 reported records.
GlaxoSmithKline, LLC. accounted for 38.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Viberzi by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.82 | 38.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.27 | 24.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.84 | 19.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.50 | 17.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $75.43 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.82 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 106 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
106 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 973 | 167 |
| Atorvastatin Calcium | Atorvastatin Calcium | 823 | 160 |
| Pantoprazole Sodium | Pantoprazole Sodium | 700 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 536 | 87 |
| Omeprazole | Omeprazole | 461 | 80 |
| Furosemide | Furosemide | 413 | 84 |
| Metformin Hcl | Metformin Hcl | 361 | 75 |
| Lisinopril | Lisinopril | 360 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 359 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 338 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 331 | 74 |
| Gabapentin | Gabapentin | 330 | 72 |
| Potassium Chloride | Potassium Chloride | 327 | 59 |
| Sertraline Hcl | Sertraline Hcl | 302 | 47 |
| Losartan Potassium | Losartan Potassium | 294 | 65 |
| Simvastatin | Simvastatin | 292 | 51 |
| Trazodone Hcl | Trazodone Hcl | 291 | 57 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 285 | 51 |
| Meloxicam | Meloxicam | 278 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 278 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 268 | 86 |
| Eliquis | Apixaban | 266 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 253 | 34 |
| Allopurinol | Allopurinol | 241 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 226 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 216 | 41 |
| Bupropion Xl | Bupropion Hcl | 194 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 194 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 154 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 32 |
| Tramadol Hcl | Tramadol Hcl | 153 | 34 |
| Alendronate Sodium | Alendronate Sodium | 151 | 22 |
| Xarelto | Rivaroxaban | 150 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 66 |
| Jardiance | Empagliflozin | 147 | 26 |
| Temazepam | Temazepam | 143 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 143 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 141 | 25 |
| Glimepiride | Glimepiride | 135 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 133 | 113 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 133 | 19 |
| Cefdinir | Cefdinir | 132 | 97 |
| Carvedilol | Carvedilol | 129 | 21 |
| Pregabalin | Pregabalin | 122 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 122 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 121 | 31 |
| Prednisone | Prednisone | 109 | 54 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 106 | 17 |
| Mirtazapine | Mirtazapine | 103 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 18 |
| Buspirone Hcl | Buspirone Hcl | 101 | 15 |
| Alprazolam | Alprazolam | 100 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 99 | 17 |
| Metformin Hcl Er | Metformin Hcl | 99 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 22 |
| Atenolol | Atenolol | 92 | 16 |
| Donepezil Hcl | Donepezil Hcl | 89 | 14 |
| Finasteride | Finasteride | 89 | 14 |
| Mounjaro | Tirzepatide | 85 | 11 |
| Famotidine | Famotidine | 83 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 16 |
| Warfarin Sodium | Warfarin Sodium | 81 | suppressed |
| Entresto | Sacubitril/Valsartan | 75 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 74 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 15 |
| Montelukast Sodium | Montelukast Sodium | 70 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 67 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | suppressed |
| Spironolactone | Spironolactone | 63 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 56 | 12 |
| Lorazepam | Lorazepam | 55 | 23 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | suppressed |
| Sucralfate | Sucralfate | 54 | 13 |
| Ondansetron Odt | Ondansetron | 53 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 52 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 51 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 50 | 11 |
| Clonidine Hcl | Clonidine Hcl | 50 | 14 |
| Estradiol | Estradiol | 47 | 13 |
| Ozempic | Semaglutide | 47 | suppressed |
| Chlorthalidone | Chlorthalidone | 46 | suppressed |
| Ezetimibe | Ezetimibe | 46 | 11 |
| Linzess | Linaclotide | 46 | suppressed |
| Olanzapine | Olanzapine | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | suppressed |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 43 | suppressed |
| Azithromycin | Azithromycin | 42 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Methocarbamol | Methocarbamol | 41 | 17 |
| Methylprednisolone | Methylprednisolone | 41 | 40 |
| Valsartan | Valsartan | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 36 | 21 |
| Fluconazole | Fluconazole | 36 | 21 |
| Digoxin | Digoxin | 34 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Premarin | Estrogens, Conjugated | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Primidone | Primidone | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Viberzi | Eluxadoline | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Captopril | Captopril | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $75.43 · 5 records | GlaxoSmithKline, LLC. | AREXVY, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error